Answers are grounded in this paper and cite their sources.
While post-transplantation cyclophosphamide (PTCy)-based prophylaxis of graft-versus-host disease (GVHD) was increasingly used not only in haploidentical transplantation but also in transplantation from matched related donors, its benefit in the setting of matched non-sibling donors (MNSD) had not been discussed or reported. A 70-year-old Japanese male who was diagnosed with acute myeloid leukemia with internal-tandem duplication of the FLT3 gene was treated with intensive chemotherapy and quizartinib. After one cycle of consolidation, he was transplanted from an HLA 8/8 matched daughter. GVHD prophylaxis consisted of PTCy, tacrolimus, and mycophenolate mofetil. Neutrophil engraftment was attained at day 16, and he was still in remission at 1 year without complication, but except or grade II acute skin GVHD. Although there had been few reports on PTCy-based GVHD prophylaxis in transplantation from MNSD, our report suggested that these patients could benefit from this type of GVHD prophylaxis.
No takes yet. Share an insight, caveat, or question.
Ebisawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: